MSCs modified by rAd‐NK4 apply negative effects on the growth and migration of liver cancer cells and tumor angiogenesis, which are associated with the inhibition of Erk1/2 phosphorylation, providing a new strategy for HCC targeted therapy.44 The gene discussed is IL32; the disease is neoplasm.